Your session is about to expire
← Back to Search
Other
CSJ117 for Chronic Obstructive Pulmonary Disease
Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 2, 6 and 12 weeks
Summary
This trial is testing a new inhaled medication called CSJ117 to help people with COPD who still have symptoms despite using standard treatments. The medication aims to reduce lung inflammation and improve breathing.
Eligible Conditions
- Chronic Obstructive Pulmonary Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 2, 6 and 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 2, 6 and 12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change from baseline in E-RS score
Secondary study objectives
Accumulation ratio (Racc) of CSJ117
Change from baseline in CAT score
Change from baseline in SGRQ-C score
+11 moreTrial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: CSJ117 8mgExperimental Treatment1 Intervention
Intervention: Drug: CSJ117
Group II: CSJ117 4mgExperimental Treatment1 Intervention
Intervention: Drug: CSJ117
Group III: CSJ117 PlaceboPlacebo Group1 Intervention
Intervention: Drug: Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CSJ117
2021
Completed Phase 2
~70
Find a Location
Who is running the clinical trial?
Novartis PharmaceuticalsLead Sponsor
2,904 Previous Clinical Trials
4,207,977 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger